TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02292550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor
Study: NCT02370732

Intervention type: OTHER
Group type: OTHER
Intervention: Alcohol
Description: A weight based dose of alcohol will be administered during each study day.
Study: NCT02292550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: CDK 4/6 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK inhibitor
Study: NCT03867617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regulatory T cells
Description: Single infusion of expanded regulatory T cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Treatment during first month post-transplant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bone marrow
Description: Infusion of donor bone marrow cells.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney transplant
Description: Living donor kidney transplantation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Living donor kidney transplantation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive drug therapy
Description: Immunosuppressive drug therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunosuppressive drug therapy
Description: Immunosuppressive drug therapy.
Study: NCT02611427

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education/Self-efficacy
Description: The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: The education group will receive information about safe physical activity.
Study: NCT02812966

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lutonix
Description: Drug Coated Balloons

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IN.PACT
Description: Drug Coated Balloons
Study: NCT02728245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dienogest
Description: Dienogest 2mg po qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dienogest
Description: Dienogest 2mg po qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: Placebo 1 table po qd

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: conservative surgery without intent to oophorectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Surgery
Description: conservative surgery without intent to oophorectomy
Study: NCT04639154

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinea plane block
Description: ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinea plane block
Description: ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinea plane block
Description: ESPPB will be performed at the T5 and T8 levels of the spine using an in-plane approach. A real-time ultrasound machine will be used to evaluate block performance. A high frequency linear ultrasound probe will be placed longitudinally at a distance of 3 cm from the midline. After identifying the erector spinae muscle and transverse processes, we will insert a 22 G, 100-mm needle after standard skin disinfection. It will be inserted in a caudal-to-cephalad direction using a sterile probe cover until the tip lay in the interfacial plane deep into the erector spinae muscle. This plane will be opened following hydrolocalization with normal saline then 30 mL of 0.25% bupivacaine will be injected slowly, with or without adjuvants, and aspirate every 5 ml to ensure block performance.
Study: NCT00418847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: Target dose of 320 mg/m\^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA \> 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
Study: NCT02518711

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Teacher Program
Description: This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
Study: NCT02008864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Senna
Description: (7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet/ 2 times per day
Study: NCT02714829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inject BMP
Description: Injection of ExcelOS-inject(beta-TCP) containing rhBMP-2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ExcelOS-inject
Description: Injection of ExcelOS-inject(beta-TCP) without rhBMP-2.
Study: NCT03596424

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Intraoperative bolus and infusion (see arm description)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Intraoperative bolus and infusion (see arm description)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine Hydrochloride and Ketamine Hydrochloride
Description: Intraoperative bolus and infusion (see arm description)
Study: NCT02292550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: ALK inhibitor
Study: NCT02680769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 mg of citrate Mg
Description: This group will take an oral supplementation of 300 mg of citrate magnesium

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will take a placebo
Study: NCT00695084

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy
Description: Intensive practice with the hemiparetic arm for 30 contact hours
Study: NCT03218293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIPC device (IPC-906X)
Description: Patients in the RIPC group had five cycles of 5-min cuff inflation followed by 3-min deflation to the bilateral upper arm after thrombolysis.
Study: NCT00524745

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Description: Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
Study: NCT03318640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
Study: NCT02759146

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reflexology
Description: Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditative Practices
Description: Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
Study: NCT01842620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Oral antidiabetic agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral antidiabetic agent
Study: NCT02984826

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength training
Description: The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ergonomic and posture
Description: The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
Study: NCT03552549

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: Polyethylene glycol (PEG)12000 Interferon alfa 2-b subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INTRON A
Description: Interferon alfa-2b, recombinant for intravenous injection.
Study: NCT01386099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSN821
Description: Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo twice a day for 12 weeks.
Study: NCT02868723

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aggressive Management
Description: With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
Study: NCT00109486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Study: NCT01321697

Intervention type: PROCEDURE
Intervention: Routine Leg edema and groin dissection
Description: The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
Study: NCT01732679

Intervention type: OTHER
Intervention: rehabilitation
Description: Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
Study: NCT05730452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risk-stratified discharge and post-discharge care
Description: Interventional intensity is based on predicted risk. Predicted risk based on previously developed prediction algorithms.~Low risk: receive discharge education and counselling only; Moderate risk: Discharge education and counselling + 1 post-discharge follow-up referral at day 7; High risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14); Very high risk: Discharge education and counselling + 3 post-discharge follow-up referrals (D2, D7, D14, D28)
Study: NCT00359671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK6592
Description: MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: MK6592
Description: MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: comparator: docetaxel
Description: docetaxel, delivered as a standard IV infusion.
Study: NCT00120315

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: esomeprazole
Description: esomeprazole, original Nexium, 40 mg pills Up to once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: esomeprazole
Description: esomeprazole, original Nexium, 40 mg pills Up to once a day

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Helicobacter pylori c-13 breath test
Description: Breath test done at entry to find Helicobacter pylori

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Helicobacter pylori c-13 breath test
Description: Breath test done at entry to find Helicobacter pylori
Study: NCT02853916

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg InSea2®

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 250 mg InSea2®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00243152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: : 25mg and 50mg tablets
Study: NCT03497078

Intervention type: OTHER
Group type: OTHER
Intervention: Bone scintigraphy
Description: Comparison of image quality between new collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on bone scintigraphy.
Study: NCT00243152

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Lamotrigine)
Description: Sugar pill manufactured to mimic Lamotrigine tablets
Study: NCT02749591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy
Description: After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror therapy
Description: After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
Study: NCT04083443

Intervention type: OTHER
Intervention: Additional blood sampling
Description: Blood samples will be taken to assess antimicrobial drug concentrations and microbial DNA blood counts. Per patient, at least 5 and up to 15 samples for drug concentrations and at least 3 and up to 6 samples for DNA counts are taken for a duration of up to 3 days.
Study: NCT03430011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCARH125
Description: Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by one dose of JCARH125 administered intravenously (IV).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JCARH125 + anakinra
Description: Participants will undergo leukapheresis to isolate PBMCs for the production of JCARH125. During JCARH125 production, participants may receive bridging chemotherapy for disease control. Following successful generation of JCARH125 product, participants will receive a course of lymphodepleting chemotherapy followed by two doses of anakinra administered subcutaneously and one dose of JCARH125 administered IV. Subjects receive anakinra for 5 consecutive days following JCARH125 infusion.
Study: NCT03799848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: Oral tablet
Study: NCT03393481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: MAA868 dose 1 and dose 2, single administration, subcutaneous,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAA868
Description: MAA868 dose 1 and dose 2, single administration, subcutaneous,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40 mg, o.d X 10 days
Study: NCT04223583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride
Description: The standard first-line chemotherapy regimen (adriamycin + ifosfamide) failed
Study: NCT01337882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forearm venous occlusion plethysmography study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin \[100, 300 \& 1000 pmol/min\]; acetylcholine \[5, 10 \& 20 µg/min\]) and -independent \[sodium nitroprusside \[2, 4 \& 8 µg/min\]; verapamil \[10, 30 \& 100 µg/min\]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
Study: NCT05136807

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study: NCT05136807

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01085435

Intervention type: DEVICE
Intervention: S-ICD System
Description: The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.

Intervention type: DEVICE
Intervention: S-ICD System
Description: The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
Study: NCT03599245

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
Study: NCT02518412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tDCS
Description: Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
Study: NCT00167557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon
Description: 180mcg SC weekly starting 30 days post transplant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: Liver biopsies performed at 9 points in time from time of liver transplant